| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1(I) Collagen Promoter Exhibit Growth Retardation, Osteomalacia, and Disturbed Phosphate Homeostasis
Department of Surgical Sciences (T.L., R.M., K.B.J.), Uppsala University Hospital, SE-751 85 Uppsala, Sweden; Department of Medical Sciences (T.L., O.L.), Uppsala University Hospital, SE-751 85 Uppsala, Sweden; Endocrine Unit (E.S., H.J.), Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114; Division of Endocrinology (C.O.), Department of Internal Medicine, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden; and Departments of Pediatrics and Human Genetics (H.S.T.), McGill University, and The McGill University-Montreal Children’s Hospital Research Institute, Montreal, Quebec, Canada H3Z 2Z3
Address all correspondence and requests for reprints to: Kenneth B. Jonsson, Department of Surgical Sciences, University Hospital, SE-751 85, Uppsala, Sweden. E-mail: Kenneth.Jonsson{at}surgsci.uu.se.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1(I) collagen promoter, in cells of the osteoblastic lineage. At 8 wk of age, transgenic mice were smaller (body weight = 17.5 ± 0.57 vs. 24.3 ± 0.37 g), exhibited decreased serum Pi concentrations (1.91 ± 0.27 vs. 2.75 ± 0.22 mmol/liter) and increased urinary Pi excretion when compared with wild-type littermates. The serum concentrations of human FGF-23 (undetectable in wild-type mice) was markedly elevated in transgenic mice (>7800 reference units/ml). Serum PTH levels were increased in transgenic mice (231 ± 62 vs. 139 ± 44 pg/ml), whereas differences in calcium and 1,25-dihydroxyvitamin D were not apparent. Expression of Npt2a, the major renal Na+/Pi cotransporter, as well as Npt1 and Npt2c mRNAs, was significantly decreased in the kidneys of transgenic mice. Histology of tibiae displayed a disorganized and widened growth plate and peripheral quantitative computerized tomography analysis revealed reduced bone mineral density in transgenic mice. The data indicate that FGF-23 induces phenotypic changes in mice resembling those of patients with ADHR, OOM, and XLH and that FGF-23 is an important determinant of Pi homeostasis and bone mineralization. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In ADHR, missense mutations in FGF23 (R176Q, R179W, and R179Q) change Arg residues within a subtilisin-like proprotein convertase recognition site (176RHTR179) (4, 5). Mammalian or insect cells expressing wild-type human FGF-23 (hFGF-23) secrete, in addition to the expected 32-kDa full-length protein, a 12- to 16-kDa carboxy-terminal fragment and a 20-kDa amino-terminal fragment (6, 7, 8). In contrast, cells expressing mutant FGF-23 secrete only the full-length protein, suggesting that the mutations prevent proteolytic processing of FGF-23 (4). There is evidence to suggest that FGF-23, or fragments thereof, may also be a substrate for PHEX, a type II membrane-associated zinc metallopeptidase that is expressed predominantly in cells of the osteoblast lineage (9, 10, 11). Although the data are conflicting, recent observations suggest that PHEX may cleave FGF-23 near the 176RHTR179 site (12, 13, 14, 15).
FGF-23 circulates at measurable levels in normal individuals, and serum levels are elevated in OOM patients and most XLH patients (16, 17). Furthermore, FGF-23 mRNA and protein are highly expressed in OOM tumors, and when these tumors are successfully removed, the circulating FGF-23 levels in patients return to within the normal range (2, 18, 19), suggesting involvement of the factor in the pathogenesis of OOM. Elevated levels of FGF-23 have also been reported in other human diseases involving disturbed Pi homeostasis, such as chronic kidney disease (20, 21) and fibrous dysplasia (22).
Direct evidence for the involvement of FGF-23 in Pi physiology came from studies where recombinant, intact FGF-23 was given parenterally to rodents or through sc implantation of cells expressing FGF-23 in immunocompromised animals. These animals develop hypophosphatemia, hyperphosphaturia, and osteomalacia (23). Data from transgenic animals expressing FGF-23 ubiquitously under the control of the CAG promoter also indicated disturbed Pi homeostasis (24), whereas ablation of the FGF23 gene in mice resulted in significant hyperphosphatemia (25). Conflicting data on the ability of FGF-23 to inhibit Pi transport in renal cells in vitro (12, 26) makes it uncertain whether the effect seen in the in vivo models are direct or indirect. Also, it remains to be established whether the skeletal findings in these animal models are solely dependent on the systemic effects of FGF-23 or occur as result of a direct effect of FGF-23 on bone.
The tissue responsible for FGF-23 production has not been clearly identified. However, recent data demonstrate that the skeleton appears to be the major site of FGF-23 expression and that the Hyp mouse, which displays characteristics similar to human XLH patients, exhibits increased FGF-23 mRNA levels in calvaria, mandible, and long bones when compared with wild-type littermates (14). FGF-23 mRNA is also produced by active osteoblasts in fractures and in the lesions seen in patients with fibrous dysplasia (22).
The aim of the present study was to investigate the long-term effects of FGF-23 in vivo. To achieve this goal, we generated transgenic mice expressing hFGF-23 under the control of the 1(I) collagen promoter, allowing FGF-23 production in cells of the osteoblast lineage. We demonstrate in this model that FGF-23 induces phenotypic changes similar to those of patients with ADHR, OOM, and XLH and that FGF-23 is an important determinant of Pi homeostasis, vitamin D metabolism, and bone mineralization.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1(I) collagen promoter contained in the pcDNA1 vector. Restriction endonuclease digestions and nucleotide sequence analysis confirmed the correct orientation of the construct (data not shown). Nucleotide sequence analysis also confirmed the presence of an in-frame stop codon and of the native Kozak consensus sequence upstream of the translation initiation codon. The construct insert, containing the 2.3-kb fragment of the mouse 1(I) collagen promoter, 753 bp encoding hFGF-23 and 750 bp from the pcDNAI vector was released from the vector by digestion with HindIII and ScaI and purified according to standard techniques. Microinjections into the pronucleus of fertilized oocytes were performed at the Center for Transgene Technology (Karolinska Institute, Stockholm, Sweden). Founder mice of the F2 (CBA X C57/BL6) strain were mated with wild-type mice to establish individual transgenic lines. Mice were maintained in a virus- and parasite-free barrier facility under a 12-h light/12-h dark cycle at Uppsala University Hospital and weaned at 18 d of age onto autoclaved rodent chow containing 0.75% Pi, 0.98% calcium and 1500 U/kg vitamin D (R36, Lactamin, Stockholm, Sweden). The project was approved by the local ethics committee (approval number C 153/1).
Genotyping
For genotyping, genomic DNA was extracted from the tails using standard techniques. FGF-23 transgenic mice were detected using Southern blotting or RT-PCR with the primer pairs: forward; 5'-ctctgggtctgtgccttgtgc-3'; reverse 5'-ggagtacgggggtgggttcat-3' (generating a fragment of 444 bp, corresponding to 123–567 of FGF-23 mRNA) or forward; 5'-ttcacttcaacacccccatac-3'; reverse; 5'-aatagcaaagcaagcaagagt-3' (generating a fragment of 698 bp, corresponding to 3019–3717 of the construct). For Southern blotting, the DNA was digested with SacI, electrophoresed through a 1% agarose gel, blotted onto a nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). A full-length 32P-labeled FGF-23 probe was synthesized using the Megaprime Labeling kit (Amersham Pharmacia Biotech). The membrane was hybridized at 68 C overnight (
1 million counts/ml) in QuickHyb Hybridization Solution (Stratagene, La Jolla, CA). The membrane was rinsed in standard saline citrate buffer according to standard procedures. On autoradiographs, FGF-23 transgenic mouse DNA produced a specific band at 3.1 kb. The correct genotype was also confirmed by measuring circulating levels of hFGF-23 using an ELISA detecting the C-terminal portion of hFGF-23 (Immutopics, San Clemente, CA), which also served as assessment of expression of the transgene. Further proof of expression of the transgene was obtained by in situ hybridization on decalcified bone sections.
Tissue preparation
For histological analysis, mice expressing hFGF-23 and sex-matched wild-type littermates were killed by cervical dislocation at 3 d, 18 d, and 8 wk of age. Tissues from mice expressing hFGF-23 and wild-type mice were fixed in 4% formalin at 4 C overnight. In selected cases, hindlimbs were decalcified in 20% EDTA in PBS for 3 wk, and paraffin blocks were prepared by standard histological procedures. For plastic embedding, samples were fixed in 4% formalin, processed and embedded in methylmethacrylate according to standard procedure (27, 28).
Histology
Paraffin samples were cut into 6-µm sections. The sections were stained with hematoxylin and eosin (H&E). Methylmethacrylate samples were cut into 3-µm sections and stained with von Kossa and Goldner’s Trichrome stain. Histology was performed on 18-d- or 8-wk-old tibiae.
In situ hybridization
A 35S-labeled antisense RNA probe was transcribed from a linearized plasmid encoding hFGF-23 using a T7 RNA polymerase. The probes were purified by gel filtration through a Micro Bio-Spin chromatography column (Probe Quant, GM 50 Micro Columns, Amersham Pharmacia Biotech). Deparaffinized sections were hybridized for 12 h and then rinsed in standard saline citrate buffer according to standard procedures. The slides were covered with photographic emulsion and were exposed at 4 C for 14 d. Slides were developed and stained with H&E.
Immunohistochemistry
For immunohistochemical detection of Npt2a, frozen renal sections were fixed in 4% formalin at 4 C for 10 min. A polyclonal rabbit antimouse/human NPT2 (Alpha Diagnostic International, San Antonio, TX) antibody was used as primary antibody and a biotinylated IgG antirabbit (Vector Laboratories, Järfälla, Sweden) as secondary antibody. For development, the Avidin-Biotin-Complex kit (Vector Laboratories, Järfälla, Sweden) was used. Slides were counterstained with Mayer’s hematoxylin.
Ribonuclease protection assay
Antisense RNA probes for P450c1, P450c24 (29), Npt1, Npt2a (30), Npt2c (31), and ß-actin were prepared by transcription of subcloned cDNA fragments using either T7 or T3 RNA polymerases (Maxiscript protocol, Ambion, Inc., Austin, TX) and -32P-labeled uridine triphosphate (800 Ci/mmol; NEN Life Science Products, Boston, MA). The predicted sizes of the ribonuclease-protected fragments were: P450c1, 493 bp; P450c24, 376 bp; Npt1, 430 bp; Npt2a, 351 bp; Npt2c, 345 bp; and ß-actin, 250 bp. A linearized TRIPLEscript plasmid containing a 250-bp mouse ß-actin cDNA fragment was used as a control template.
The ribonuclease protection assay was performed as we described previously (31) using the HybSpeed RPA assay kit (Ambion, Inc.). Total RNA (20 µg), isolated from kidneys using the Trizol reagent (Invitrogen Life Technologies, Gaithersburg, MD), was hybridized with the appropriate riboprobes (5 x 105 cpm) at 68 C for 10 min, and treated with ribonuclease A (5 U/ml) and T1 (200 U/ml) at 37 C for 30 min. The remaining protected RNA fragments were precipitated, denatured, and resolved on a denaturing 5% acrylamide/8 M urea gel. The gel was dried and exposed to a PhosphorImager screen (Molecular Dynamics, Inc., Sunnyvale, CA) for quantitation. Results are expressed as the ratio of each transcript to ß-actin mRNA.
Biochemistry
Arterial blood was collected from anesthetized animals by cutting the axillary artery. After clotting, the blood was spun and serum collected for analysis. For urine analysis, spot urine was taken four times during 24 h. Pi and calcium were measured using the phosphorous reagent kit/calcium kit (Sigma Diagnostics Inc., St. Louis, MO). Creatinine was measured at the central laboratory, Uppsala University Hospital, Sweden. All urine samples were diluted 1:10 in 0.9% NaCl. For PTH and FGF-23, the Mouse Intact PTH kit and the Human C-terminal FGF-23 ELISA kit were used (Immutopics, San Clemente, CA). 1,25(OH)2D3 was measured by a specific RIA kit (IDS Ltd., Boldon, UK). Urine cAMP were measured using the cAMP 200 tube kit (PerkinElmer Life Science, Boston, MA). The fractional excretion index for Pi (FEI
) or calcium (FEIcalcium) was calculated as follows: FEIPi = (urine Pi/urine creatinine)/(serum Pi/serum creatinine).
Dual x-ray absorptiometry (DXA) and quantitative computerized tomography
Area bone mineral density (BMD) and bone mineral content (BMC) were measured with peripheral DXA (pDXA) Sabre and Sabre Research software (Norland Medical Systems, Inc., Fort Atkinson, WI) (32). Ex vivo measurements of the tibia were performed on excised bones placed on a 1-cm-thick Plexiglas table. All bones compared were measured in the same scan (high-resolution scan with line spacing set at 0.01 cm).
Computerized tomography was performed with the Stratec Peripheral QCT (pQCT) XCT Research M (software version 5.4B; Norland Medical Systems, Inc.) operating at a resolution of 70 µm (33). Middiaphyseal pQCT scans of the femur and tibia were performed to determine the cortical cross-sectional area, the cortical BMC, the periosteal circumference, and the cross-sectional moment of inertia. The middiaphyseal region of the long bones in mice contains mainly cortical bone. Metaphyseal pQCT scans of the proximal part of the tibia were performed to measure trabecular volumetric BMD. The scan was positioned in the metaphysis at a distance from the growth plate corresponding to 4.5% and 2.6% of the total length of the femur and tibia, respectively (an area containing cortical as well as trabecular bone). The trabecular bone region was defined by setting an inner threshold to 400 mg/mm3. The interassay coefficients of variation for the pQCT measurements were less than 2%. It should be emphasized that the DXA technique gives the area BMD, whereas the pQCT gives the real/volumetric BMD. Therefore, a factor regulating the outer dimensions of a bone will affect the area BMD (DXA) but not the volumetric BMD (pQCT).
Statistical analysis
Each group studied contained 5–10 mice. Statistical analysis was performed using the Stat Soft Statistica 6 software package. Values are expressed as mean ± SEM. Differences between wild-type and transgenic groups were calculated using Student’s independent t test. A probability of P < 0.05 was considered to be statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
). Expression was seen in bone-forming osteoblasts, which is in agreement with the observation in other transgenic animals that have been generated using a similar promoter construct (34). The FGF-23 construct was transmitted to the progeny with the expected Mendelian frequency. The number of males and females born were similar. The gross appearance of mice expressing hFGF-23 was normal during the first week of life. However, visually detectable changes in body size, shape, and length of extremities could be observed even before the end of the weaning period. Photographic and x-ray pictures of representative 8-wk-old wild-type and FGF-23 transgenic males are displayed in Fig. 2. The mean body weight of the FGF-23 transgenic mice was significantly different at d 25, and the difference increased until adult age (Fig. 3). Mean body weights were 17.5 ± 0.57 vs. 24.3 ± 0.37 g for transgenic and wild-type males, respectively, (P < 0.001) and for females 14.8 ± 0.51 vs. 19.1 ± 0.67 g (P < 0.001). At 8 wk, tibial bone lengths were 17.8 ± 0.23 vs. 13.6 ± 0.21 mm for male and 17.2 ± 0.11 vs. 13.6 ± 0.13 mm for female wild-type and transgenic mice, respectively.
|
|
|
) and 18 d (Table 1B) of age. At 8 wk, mice expressing hFGF-23 revealed low serum Pi but normal serum calcium levels compared with wild-type controls. Creatinine was unchanged in FGF-23 transgenic mice compared with wild-type. Also, elevated levels of PTH were observed in FGF-23 transgenic mice. However, no difference in 1,25(OH)2D3 levels were observed in mice expressing hFGF-23 compared with wild-type. Notably, female FGF-23 transgenic mice exhibited higher levels of circulating FGF-23 than male FGF-23 transgenic mice (Table 1A). Circulating PTH and 1,25(OH)2D3 levels as well as Pi and calcium were also measured at d 18 (Table 1B). Already at this time point, mice expressing hFGF-23 revealed elevated PTH. In contrast to the levels in 8-wk-old mice, circulating 1,25(OH)2D3 levels were significantly lower in mice expressing hFGF-23 compared with wild type.
|
). As an increase in PTH levels was observed, urinary cAMP in 8-wk-old mice was measured. No difference in urinary cAMP levels was observed, possibly indicating a PTH resistance in mice expressing hFGF-23.
Bone phenotype
Area BMD and area BMC of 8-wk-old FGF-23 transgenic mice was determined on tibias by DXA. BMC was lower in mice expressing hFGF-23 compared with wild-type depending on decreased areal density (Table 2). To investigate the effect on different bone compartments in more detail we performed pQCT. Mice expressing hFGF-23 had decreased volumetric cortical as well as trabecular BMD in comparison to wild-type. Also, the cortical dimensions including periosteal circumference and cortical thickness were reduced. The results from these measurements are presented in Table 2.
|
). Bony trabeculae in the primary spongiosa appeared to be thicker with increased connectivity but contained very little mineral (Fig. 4, A and B). Furthermore, in the secondary spongiosa, the amount of trabecular bone was reduced. Lastly, in the metaphysis, islands of chondrocytes surrounded by thick unmineralized bone matrix were observed in mice expressing hFGF-23 (Fig. 4, A and B). Von Kossa stainings generally revealed a decreased amount of mineralized matrix in FGF-23 transgenic mice (Fig. 4B). Tibiae from 18-d-old mice were examined and at this age, mineralization was also impaired (Fig. 4C). The thickness of cortical bone was reduced and both cortical and trabecular bone contained an increased amount of osteoid and decreased amounts of mineralized bone in relation to osteid (Fig. 4D).
|
). Moreover, immunohistochemistry of renal sections revealed that Npt2a protein abundance was also reduced in mice harboring the hFGF23 transgene (Fig. 6). Renal expression of the Npt2c (Fig. 5B) and Npt1 (males only) (Fig. 5C) mRNAs, relative to ß-actin mRNA, was also significantly decreased in transgenic mice when compared with normal animals.
|
|
-hydroxylase and 24-hydroxylase mRNAs was also compared in wild-type and transgenic mice. At 8 wk, 1-hydroxylase abundance, relative to ß-actin mRNA, was reduced in transgenic male mice (not significant), but was increased in transgenic female mice (Fig. 5D). Thus, the renal 1-hydroxylase expression followed the same pattern as the circulating levels of 1,25(OH)2D3. Renal 24-hydroxylase mRNA, relative to ß-actin mRNA, was clearly increased in transgenic males and also in females (not significant) (Fig. 5E).
Parathyroid glands
To further explore the elevated levels of circulating PTH in mice expressing hFGF-23, we examined the parathyroid glands histologically at 8 wk. The parathyroid glands in mice expressing hFGF-23 were hypertrophic, but no structural changes were observed (Fig. 7).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Recent reports suggest that FGF-23 is expressed mainly in active osteoblastic cells (15). FGF-23 expression is also seen in the histologically disorganized bone lesions of fibrous dysplasia (22). It is unclear whether bone derived FGF-23 is acting locally on bone cells or whether its actions are endocrine. In our model, FGF-23 is produced in bone. However, FGF-23 is readily secreted and released into the circulation and high levels of circulating FGF-23 were observed in this transgenic model. Our data, therefore, cannot differentiate between local skeletal actions and systemic effects of FGF-23.
The skeletal phenotype of the FGF-23 transgenic mice share many characteristics with other rachitic animal models. For example the Hyp mouse, which carries a deletion of the PHEX gene, shows a similar bone phenotype as well as hypophosphatemia secondary to decreased renal expression of Npt2a, Npt2c, and Npt1 (31). Notably, circulating levels of FGF-23 are elevated approximately 20-fold in this model (35) (Tenenhouse, H. S., and T. Yamashita, unpublished data). It is possible that the bone phenotype in the Hyp and the FGF-23 transgenic models could be caused by insufficient Pi at the mineralization front. However, Npt2a knockout mice do not exhibit rickets and osteomalacia despite significant hypophosphatemia (36, 37). Moreover, in that model, PHEX expression is intact (31) and serum levels of FGF-23 are significantly lower relative to wild-type littermates (Tenenhouse, H. S., and T. Yamashita, unpublished data). This suggests that mechanisms other than hypophosphatemia are involved in the development of rickets in the animal model presented here.
It is well known that lack of vitamin D, as in the 1(OH)ase null mice (38), or lack of vitamin D receptor (VDR) signaling, as in the VDR knockout, causes rickets and osteomalacia. Because vitamin D metabolism in FGF-23 transgenic animals is disturbed, this could contribute to the rickets observed. In the VDR null mice, the hypertrophic chondrocyte layer exhibits decreased apoptosis (39) and in vitro data suggest that Pi is capable of inducing apoptosis in chondrocytes (40). However, a histologically normal growth plate can be maintained in the VDR null mice (41) by increasing the intake of dietary calcium and phosphorous. Thus, neither hypophosphatemia alone nor vitamin D deficiency, under conditions where the supply of calcium and phosphorous is adequate, is sufficient to induce rickets/osteomalacia. We therefore propose that other effects of FGF-23 contribute to demineralization of bone.
Hypophosphatemia is normally a strong stimulator of the renal 1-hydroxylase, leading to a rise in the serum concentration of 1,25(OH)2D3 (42). However, in young FGF-23 transgenic mice, 1,25(OH)2D3 levels are inappropriately low. This suggests dysregulation of vitamin D metabolism in the presence of high circulating levels of FGF-23. Indeed, this is a hallmark of hypophosphatemic disorders in which high levels of FGF-23 have been demonstrated. For example, patients with OOM and XLH have either low or normal serum 1,25(OH)2D3 levels in the face of significant hypophosphatemia (16, 17). Also, in contrast to the Npt2a knockout mice, which have elevated serum 1,25(OH)2D3 levels (29), Hyp mice have inappropriately normal 1,25(OH)2D3 levels and also fail to respond to a low Pi challenge with increased renal 1-hydroxylase activity and elevated serum 1,25(OH)2D3 (29, 43). This suggests that FGF-23 modulates the increased activity of the 1-hydroxylase in response to low Pi intake. Furthermore, as in the case of Hyp mice, FGF-23 transgenic mice clearly have increased expression of 24-hydroxylase mRNA in their kidneys (43). The latter could contribute to the inability of Hyp mice and FGF-23 transgenic mice to increase their serum 1,25(OH)2D3 concentration in response to hypophosphatemia.
In adult mice, the difference between circulating 1,25(OH)2D3 levels in wild-type compared with FGF-23 transgenic animals disappeared. This could be due to an adaptive mechanism in the renal cells expressing 1-hydroxylase or the result of a FGF-23 receptor down-regulation. More likely, the development of secondary hyperparathyroidism may facilitate the maintenance of normal levels of 1,25(OH)2D3 because PTH is a known stimulator of 1-hydroxylase mRNA and 1,25(OH)2D3 production (44). Interestingly, 1-hydroxylase mRNA levels were higher in female than in male transgenic mice. The reason for this remains unclear but could be related to differences in the levels of systemic Phex expression or to sex-specific hormonal differences. Of note, FGF-23 levels were for unknown reasons also higher in female than in male transgenic mice.
PTH levels were clearly raised in FGF-23 transgenic mice as early as 18 d of age and remained increased in adulthood. Histology of the parathyroid glands demonstrates hypertrophy but no adenomas. The elevated levels of PTH in the FGF-23 transgenic animals, as well as in Hyp mice (45, 46) may be crucial for maintaining normocalcemia because Hyp mice with targeted deletion of the PTH gene suffer from early lethality due to hypocalcemia (47). The elevated PTH levels in the Hyp and FGF-23 transgenic mouse models may also contribute to the renal Pi wasting and ensuing hypophosphatemia (45, 46).
The cause of the secondary hyperparathyroidism in the FGF-23 transgenic animals is not entirely clear. The mice expressing hFGF-23 had normal serum calcium levels, and no increase in urinary calcium excretion. Additionally, low Pi levels should counteract development of parathyroid gland hypertrophy because Pi per se is known to stimulate parathyroid cell proliferation (48). It is possible that the inappropriately low levels of 1,25(OH)2D3 may contribute to the parathyroid hypertrophy. 1,25(OH)2D3 has a direct suppressive effect on the parathyroid gland (49, 50) and lack of 1,25(OH)2D3 could therefore potentially lead to the observed hypertrophy. It remains to be investigated whether FGF-23 has a direct stimulatory effect on the chief cells in the parathyroid glands. Interestingly, patients with renal failure have been found to have high levels of circulating FGF-23 in the setting of low 1,25(OH)2D3 and secondary hyperparathyroidism (20, 21). Thus, the FGF-23 transgenic mouse model offers new opportunities to study the relative contribution of low 1,25(OH)2D3, low Pi, and high FGF-23 to the development of secondary hyperparathyroidism.
Normal serum Pi levels are maintained mainly through the regulation of Npt2a activity in the kidneys (36). Although a specific Pi sensor has not yet been identified, it is well established that the kidney responds to changes in dietary Pi intake (51) by adjusting the reabsorption of filtered Pi from the proximal tubule. Pi deprivation leads to up-regulation of Npt2a, whereas Pi loading down-regulates Npt2a and thus increases urinary excretion of Pi (52). Npt2a is also a target for the regulation of renal Pi reabsorption by PTH (52, 53). We found that renal Npt2a mRNA and protein expression are clearly decreased in FGF-23 transgenic mice, explaining the mechanism for the urinary loss of Pi and subsequent hypophosphatemia. The down-regulation of Npt2a despite the long-term hypophosphatemia prevailing in the FGF-23 transgenic mice indicates that FGF-23 may act directly to reduce renal Npt2a expression. Notably, it was recently reported that FGF-23 down-regulates Npt2a expression in opossum kidney cells through FGFR3 signaling (26). We also found reduced renal mRNA expression of other sodium-dependent Pi transporters, including the less abundantly expressed Npt1 (54), and the novel renal brush-border membrane cotransporter Npt2c (31). Taken together, our data suggest that the FGF-23-mediated decrease in renal Pi reabsorption in the transgenic model may be the result of the down-regulation of all three sodium/Pi cotransporters, consistent with similar findings recently reported in Hyp mice (31).
In summary, this study describes a novel transgenic mouse model in which FGF-23 is overexpressed in cells of the osteoblast lineage. These transgenic animals are likely to provide further insights into the physiological role of FGF-23 in Pi homeostasis and bone biology.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
T.L. and R.M. contributed equally to this work.
Abbreviations: ADHR, Autosomal dominant hypophosphatemic rickets; BMC, bone mineral content; BMD, bone minderal density; DXA, dual x-ray absorptiometry; 1,25(OH)2D3, 1,25-dihydroxyvitamin D3; FEI, fractional excretion index; FGF, fibroblast growth factor; H&E, hematoxylin and eosin; OOM, oncogenic osteomalacia; pDXA, peripheral DXA; PHEX, a Pi-regulating protein with homologies to endopeptidases encoded by a gene on the X chromosome; Pi, phosphate; pQCT, peripheral quantitative computerized tomography; VDR, vitamin D receptor; XLH, X-linked hypophosphatemia.
Received December 31, 2003.
Accepted for publication February 18, 2004.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-hydroxylase by phosphate. Endocrinology 142:1124–1129 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol 129:1421–1432-hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Proc Natl Acad Sci USA 98:7498–7503-hydroxylase gene expression in the proximal renal tubule. Endocrinology 143:587–595-hydroxylase gene expression by phosphorus in X-linked hypophosphatemic (hyp) mice. Endocrinology 144:3463–3468-hydroxylase gene and its splice variant. Recent Results Cancer Res 164:157–167[Medline]
This article has been cited by other articles:
 |
|
 |
|
  R. Samadfam, C. Richard, L. Nguyen-Yamamoto, I. Bolivar, and D. Goltzman Bone Formation Regulates Circulating Concentrations of Fibroblast Growth Factor 23 Endocrinology, November 1, 2009; 150(11): 4835 - 4845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. I. Mirza, T. Hansen, L. Johansson, H. Ahlstrom, A. Larsson, L. Lind, and T. E. Larsson Relationship between circulating FGF23 and total body atherosclerosis in the community Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3125 - 3131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Liu, X. Bai, H. Wang, A. Karaplis, D. Goltzman, and D. Miao Hypophosphatemia-mediated hypotension in transgenic mice overexpressing human FGF-23 Am J Physiol Heart Circ Physiol, October 1, 2009; 297(4): H1514 - H1520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liu, W. Tang, J. Fang, J. Ren, H. Li, Z. Xiao, and L. D. Quarles Novel Regulators of Fgf23 Expression and Mineralization in Hyp Bone Mol. Endocrinol., September 1, 2009; 23(9): 1505 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. David, A. Martin, A.-M. Hedge, and P. S. N. Rowe Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator Endocrinology, September 1, 2009; 150(9): 4012 - 4023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Gattineni, C. Bates, K. Twombley, V. Dwarakanath, M. L. Robinson, R. Goetz, M. Mohammadi, and M. Baum FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 Am J Physiol Renal Physiol, August 1, 2009; 297(2): F282 - F291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Masi, A. Gozzini, A. Franchi, D. Campanacci, A. Amedei, A. Falchetti, F. Franceschelli, G. Marcucci, A. Tanini, R. Capanna, et al. A Novel Recessive Mutation of Fibroblast Growth Factor-23 in Tumoral Calcinosis J. Bone Joint Surg. Am., May 1, 2009; 91(5): 1190 - 1198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Farrow, S. I. Davis, L. J. Summers, and K. E. White Initial FGF23-Mediated Signaling Occurs in the Distal Convoluted Tubule J. Am. Soc. Nephrol., May 1, 2009; 20(5): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Berndt and R. Kumar Novel Mechanisms in the Regulation of Phosphorus Homeostasis Physiology, February 1, 2009; 24(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Razzaque Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant., January 1, 2009; 24(1): 4 - 7. [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, L. Vierthaler, W. Tang, J. Zhou, and L. D. Quarles FGFR3 and FGFR4 Do not Mediate Renal Effects of FGF23 J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2342 - 2350. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Gal-Moscovici and S. M. Sprague Role of Bone Biopsy in Stages 3 to 4 Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(Supplement_3): S170 - S174. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice Endocr. Rev., October 1, 2008; 29(6): 726 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Medici, M. S. Razzaque, S. DeLuca, T. L. Rector, B. Hou, K. Kang, R. Goetz, M. Mohammadi, M. Kuro-o, B. R. Olsen, et al. FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis J. Cell Biol., August 11, 2008; 182(3): 459 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liu, J. Zhou, W. Tang, R. Menard, J. Q. Feng, and L. D. Quarles Pathogenic role of Fgf23 in Dmp1-null mice Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E254 - E261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Brownstein, F. Adler, C. Nelson-Williams, J. Iijima, P. Li, A. Imura, Y.-i. Nabeshima, M. Reyes-Mugica, T. O. Carpenter, and R. P. Lifton A translocation causing increased {alpha}-Klotho level results in hypophosphatemic rickets and hyperparathyroidism PNAS, March 4, 2008; 105(9): 3455 - 3460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Marsell, T. Krajisnik, H. Goransson, C. Ohlsson, O. Ljunggren, T. E. Larsson, and K. B. Jonsson Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23 Nephrol. Dial. Transplant., March 1, 2008; 23(3): 827 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Marsell, E. Grundberg, T. Krajisnik, H. Mallmin, M. Karlsson, D. Mellstrom, E. Orwoll, C. Ohlsson, K. B Jonsson, O. Ljunggren, et al. Fibroblast growth factor-23 is associated with parathyroid hormone and renal function in a population-based cohort of elderly men Eur. J. Endocrinol., January 1, 2008; 158(1): 125 - 129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, W. Tang, J. Zhou, L. Vierthaler, and L. D. Quarles Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice Am J Physiol Endocrinol Metab, December 1, 2007; 293(6): E1636 - E1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perwad, M. Y. H. Zhang, H. S. Tenenhouse, and A. A. Portale Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1{alpha}-hydroxylase expression in vitro Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1577 - F1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Krajisnik, P. Bjorklund, R. Marsell, O. Ljunggren, G. Akerstrom, K. B Jonsson, G. Westin, and T. E Larsson Fibroblast growth factor-23 regulates parathyroid hormone and 1{alpha}-hydroxylase expression in cultured bovine parathyroid cells J. Endocrinol., October 1, 2007; 195(1): 125 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S Razzaque and B. Lanske The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis J. Endocrinol., July 1, 2007; 194(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yoshiko, G. A. Candeliere, N. Maeda, and J. E. Aubin Osteoblast Autonomous Pi Regulation via Pit1 Plays a Role in Bone Mineralization Mol. Cell. Biol., June 15, 2007; 27(12): 4465 - 4474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu and L. D. Quarles How Fibroblast Growth Factor 23 Works J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1637 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Segawa, S. Yamanaka, Y. Ohno, A. Onitsuka, K. Shiozawa, F. Aranami, J. Furutani, Y. Tomoe, M. Ito, M. Kuwahata, et al. Correlation between hyperphosphatemia and type II Na-Pi cotransporter activity in klotho mice Am J Physiol Renal Physiol, February 1, 2007; 292(2): F769 - F779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, P. S N Rowe, L. Vierthaler, J. Zhou, and L D. Quarles Phosphorylated acidic serine-aspartate-rich MEPE-associated motif peptide from matrix extracellular phosphoglycoprotein inhibits phosphate regulating gene with homologies to endopeptidases on the X-chromosome enzyme activity J. Endocrinol., January 1, 2007; 192(1): 261 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Sitara, M. S. Razzaque, R. St-Arnaud, W. Huang, T. Taguchi, R. G. Erben, and B. Lanske Genetic Ablation of Vitamin D Activation Pathway Reverses Biochemical and Skeletal Anomalies in Fgf-23-Null Animals Am. J. Pathol., December 1, 2006; 169(6): 2161 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu, J. Zhou, W. Tang, X. Jiang, D. W. Rowe, and L. D. Quarles Pathogenic role of Fgf23 in Hyp mice Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E38 - E49. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhang, O. A. Ibrahimi, S. K. Olsen, H. Umemori, M. Mohammadi, and D. M. Ornitz Receptor Specificity of the Fibroblast Growth Factor Family: THE COMPLETE MAMMALIAN FGF FAMILY J. Biol. Chem., June 9, 2006; 281(23): 15694 - 15700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. White, T. E. Larsson, and M. J. Econs The Roles of Specific Genes Implicated as Circulating Factors Involved in Normal and Disordered Phosphate Homeostasis: Frizzled Related Protein-4, Matrix Extracellular Phosphoglycoprotein, and Fibroblast Growth Factor 23 Endocr. Rev., May 1, 2006; 27(3): 221 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-i. Nabeshima Toward a better understanding of klotho. Sci. Aging Knowl. Environ., March 22, 2006; 2006(8): pe11 - pe11. [Abstract] [Full Text]
|
|
|
|
|
|
F. Perwad, N. Azam, M. Y. H. Zhang, T. Yamashita, H. S. Tenenhouse, and A. A. Portale Dietary and Serum Phosphorus Regulate Fibroblast Growth Factor 23 Expression and 1,25-Dihydroxyvitamin D Metabolism in Mice Endocrinology, December 1, 2005; 146(12): 5358 - 5364. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Berndt, S. Schiavi, and R. Kumar "Phosphatonins" and the regulation of phosphorus homeostasis Am J Physiol Renal Physiol, December 1, 2005; 289(6): F1170 - F1182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yu, O. A. Ibrahimi, R. Goetz, F. Zhang, S. I. Davis, H. J. Garringer, R. J. Linhardt, D. M. Ornitz, M. Mohammadi, and K. E. White Analysis of the Biochemical Mechanisms for the Endocrine Actions of Fibroblast Growth Factor-23 Endocrinology, November 1, 2005; 146(11): 4647 - 4656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shimada, Y. Yamazaki, M. Takahashi, H. Hasegawa, I. Urakawa, T. Oshima, K. Ono, M. Kakitani, K. Tomizuka, T. Fujita, et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism Am J Physiol Renal Physiol, November 1, 2005; 289(5): F1088 - F1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Jan de Beur Tumor-Induced Osteomalacia JAMA, September 14, 2005; 294(10): 1260 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Larsson, S. I. Davis, H. J. Garringer, S. D. Mooney, M. S. Draman, M. J. Cullen, and K. E. White Fibroblast Growth Factor-23 Mutants Causing Familial Tumoral Calcinosis Are Differentially Processed Endocrinology, September 1, 2005; 146(9): 3883 - 3891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]
|
|
|
|
|
|
M. Fukagawa and J. J. Kazama With or without the kidney: the role of FGF23 in CKD Nephrol. Dial. Transplant., July 1, 2005; 20(7): 1295 - 1298. [Full Text] [PDF]
|
|
|
|
|
|
O. Gutierrez, T. Isakova, E. Rhee, A. Shah, J. Holmes, G. Collerone, H. Juppner, and M. Wolf Fibroblast Growth Factor-23 Mitigates Hyperphosphatemia but Accentuates Calcitriol Deficiency in Chronic Kidney Disease J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2205 - 2215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Tebben, K. R. Kalli, W. A. Cliby, L. C. Hartmann, J. P. Grande, R. J. Singh, and R. Kumar Elevated Fibroblast Growth Factor 23 in Women With Malignant Ovarian Tumors Mayo Clin. Proc., June 1, 2005; 80(6): 745 - 751. [Abstract] [PDF]
|
|
|
|
|
|
M. Ito, Y. Sakai, M. Furumoto, H. Segawa, S. Haito, S. Yamanaka, R. Nakamura, M. Kuwahata, and K.-i. Miyamoto Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1101 - E1109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. J. de Beur Tumoral Calcinosis: A Look into the Metabolic Mirror of Phosphate Homeostasis J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2469 - 2471. [Full Text] [PDF]
|
|
|
|
|
|
T. Larsson, X. Yu, S. I. Davis, M. S. Draman, S. D. Mooney, M. J. Cullen, and K. E. White A Novel Recessive Mutation in Fibroblast Growth Factor-23 Causes Familial Tumoral Calcinosis J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2424 - 2427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. B. Jonsson The role of fibroblast growth factor 23 in renal disease Nephrol. Dial. Transplant., March 1, 2005; 20(3): 479 - 482. [Full Text] [PDF]
|
|
|
|
|
|
R.J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T.J. Smith, K.J. McNeill, G. Jerums, X Bai, D. Miao, J. Li, D. Goltzman, et al. Type 2 Diabetes: Absence of Proteinuria Does Not Preclude Loss of Renal Function: Nonalbuminuric Renal Insufficiency in Type 2 Diabetes. Diabetes Care 27: 195-200, 2004 J. Am. Soc. Nephrol., February 1, 2005; 16(2): 284 - 290. [Full Text] [PDF]
|
|
|
|
|
|
T. O. Carpenter, B. K. Ellis, K. L. Insogna, W. M. Philbrick, J. Sterpka, and R. Shimkets Fibroblast Growth Factor 7: An Inhibitor of Phosphate Transport Derived from Oncogenic Osteomalacia-Causing Tumors J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1012 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Bai, D. Miao, J. Li, D. Goltzman, and A. C. Karaplis Transgenic Mice Overexpressing Human Fibroblast Growth Factor 23 (R176Q) Delineate a Putative Role for Parathyroid Hormone in Renal Phosphate Wasting Disorders Endocrinology, November 1, 2004; 145(11): 5269 - 5279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Dunstan, H. Zhou, and M. J. Seibel Fibroblast Growth Factor 23: A Phosphatonin Regulating Phosphate Homeostasis? Endocrinology, July 1, 2004; 145(7): 3084 - 3086. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
, Wild-type females; 
, wild-type males; 
, FGF-23 transgenic females; 
, FGF-23 transgenic males. Symbols represent mean total body weight ± SEM for n = 6 in each group.
